South Africa Begins Introduction of PREVENAR into Childhood Immunization Program



    
    - First African Nation Plans to Phase in Routine Vaccination Program
    Against Pneumococcal Disease for Infants and Young Children -

    
    COLLEGEVILLE, Pa., Sept. 15 /CNW/ -- Wyeth Pharmaceuticals, a division of
Wyeth (NYSE:   WYE), today announced that South Africa has initiated an
immunization program against pneumococcal disease with PREVENAR(R)
(Pneumococcal Saccharide Conjugated Vaccine, Adsorbed), a vaccine which helps
protect infants and young children against the seven vaccine serotypes causing
the majority of pneumococcal disease worldwide.  The South African government
launched the pneumococcal disease immunization program in the Eastern Cape
district of Ukhahlamba last week and has plans to expand the program
nationwide by the end of March 2009.
    This historic initiative will support the United Nations' Millennium
Development Goals (MDGs) to reduce child mortality in children younger than
five years of age.  Including South Africa, there are now 27 countries that
have included PREVENAR in their national immunization programs.
    According to the World Health Organization (WHO), pneumococcal disease
causes nearly 1.6 million deaths in children each year and is the leading
vaccine-preventable cause of death in children younger than five years of age
worldwide.
    "South Africa's decision to introduce PREVENAR into the national
childhood immunization schedule will bring this potentially life-saving
vaccine to children in need," says Joseph Mahady, President, Wyeth
Pharmaceuticals. "Given the documented public health benefits that have been
seen in other regions where PREVENAR is routinely used, this announcement
holds great promise for the more than one million children born every year in
South Africa."
    Given the significant burden of pneumococcal disease and the demonstrated
vaccine efficacy, in March 2007, WHO recommended priority inclusion of the
7-valent pneumococcal conjugate vaccine in national childhood immunization
programs worldwide.  Recently, the Strategic Advisory Group of Experts (SAGE)
to WHO issued a preliminary recommendation that pneumococcal disease
prevention be ranked as a very high priority on a global basis.
    PREVENAR(R), the only licensed pneumococcal conjugate vaccine, is now
available in 88 countries around the world, with more than 180 million doses
distributed.
    
    Pneumococcal Disease
    
    Pneumococcal disease affects both children and adults and is a leading
cause of illness and death worldwide.  Pneumococcal disease is caused by the
bacterium
    Streptococcus pneumoniae and describes a group of illnesses, including
invasive infections, such as bacteremia/sepsis and meningitis, as well as
pneumonia and upper respiratory tract infections, including otitis media.
    
    Important Safety Information for PREVENAR*
    
    In clinical studies (n=18,168), the most frequently reported adverse
events included injection site reactions, fever (>38 degrees C/100.4 degrees
F), irritability, drowsiness, restless sleep, decreased appetite, vomiting,
diarrhea, and rash.  Risks are associated with all vaccines, including
PREVENAR(R).  Hypersensitivity to any vaccine component, including diphtheria
toxoid, is a contraindication to its use.  PREVENAR does not provide 100
percent protection against vaccine serotypes or protect against nonvaccine
serotypes.
    
    Wyeth Pharmaceuticals
    
    Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the
areas of women's health care, infectious disease, gastrointestinal health,
central nervous system, inflammation, transplantation, hemophilia, oncology,
vaccines and nutritional products.
    Wyeth is one of the world's largest research-driven pharmaceutical and
health care products companies.  It is a leader in the discovery, development,
manufacturing and marketing of pharmaceuticals, vaccines, biotechnology
products, nutritionals and non-prescription medicines that improve the quality
of life for people worldwide.  The Company's major divisions include Wyeth
Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.
    The statements in this press release that are not historical facts are
forward-looking statements that are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied by such statements.  These risks and uncertainties include, without
limitation, the inherent uncertainty of the timing and success of, and expense
associated with, research, development, regulatory approval and
commercialization of our products and pipeline products; government
cost-containment initiatives; restrictions on third-party payments for our
products; substantial competition in our industry, including from branded and
generic products; emerging data on our products and pipeline products; the
importance of strong performance from our principal products and our
anticipated new product introductions; the highly regulated nature of our
business; product liability, intellectual property and other litigation risks
and environmental liabilities; uncertainty regarding our intellectual property
rights and those of others; difficulties associated with, and regulatory
compliance with respect to, manufacturing of our products; risks associated
with our strategic relationships; economic conditions including interest and
currency exchange rate fluctuations; changes in generally accepted accounting
principles; trade buying patterns; the impact of legislation and regulatory
compliance; risks and uncertainties associated with global operations and
sales; and other risks and uncertainties, including those detailed from time
to time in our periodic reports filed with the Securities and Exchange
Commission, including our current reports on Form 8-K, quarterly reports on
Form 10-Q and annual report on Form 10-K, particularly the discussion under
the caption "Item 1A, RISK FACTORS" in our Annual Report on Form 10-K for the
year ended December 31, 2007, which was filed with the Securities and Exchange
Commission on February 29, 2008.  The forward-looking statements in this press
release are qualified by these risk factors.  We assume no obligation to
publicly update any forward-looking statements, whether as a result of new
information, future developments or otherwise.




For further information:

For further information: Media: Lili Gordon of Wyeth Pharmaceuticals,
+1-484-865-6671, or Douglas Petkus of Wyeth, +1-973-660-5218; or Investors:
Justin Victoria of Wyeth, +1-973-660-5340 Web Site: http://www.wyeth.com

Organization Profile

WYETH PHARMACEUTICALS

More on this organization

WYETH

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890